Analysis of early postoperative complications in patients with resectable rectal cancer after neo-adjuvant chemo-radiotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2482
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Analysis of early postoperative complications in patients with resectable rectal cancer after neo-adjuvant chemo-radiotherapy ; volume:13 ; number:1 ; day:16 ; month:9 ; year:2013 ; pages:1-2 ; date:9.2013
BMC surgery ; 13, Heft 1 (16.9.2013), 1-2, 9.2013
- Urheber
-
Grimaldi, Luciano
- Beteiligte Personen und Organisationen
-
Reggio, Stefano
Pannullo, Mario
De Palma, Giovanni
Aprea, Giovanni
Amato, Bruno
Danzi, Michele
SpringerLink (Online service)
- DOI
-
10.1186/1471-2482-13-S1-A25
- URN
-
urn:nbn:de:1111-2016072926779
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Grimaldi, Luciano
- Reggio, Stefano
- Pannullo, Mario
- De Palma, Giovanni
- Aprea, Giovanni
- Amato, Bruno
- Danzi, Michele
- SpringerLink (Online service)
Ähnliche Objekte (12)
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)
Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer
Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)
Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer
Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)
Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer